Selank

Selank is a neuropeptide with pronounced anxiolytic activity and neuropsychotropic effects, demonstrated to reduce anxiety symptoms comparable to benzodiazepine anxiolytics without causing sedation, muscle relaxation, tolerance, or withdrawal syndrome.¹ The therapeutic mechanism involves enhancement of GABAergic activity to reduce nervous system excitability, combined with modulation of dopamine and serotonin availability, which collectively support both anxiolytic and cognitive-enhancing effects.² Clinical evidence supports its use in generalized anxiety disorder (GAD) and anxiety-asthenic disorders, with studies from the Institute of Molecular Genetics showing efficacy in reducing symptoms of generalized anxiety disorder and post-traumatic stress disorder while maintaining alertness.² Beyond anxiety reduction, Selank functions as a cognitive enhancer improving short-term and long-term memory, focus, and sustained attention, with animal studies demonstrating enhancement of learning and memory formation and support for synaptic plasticity.² The peptide also exhibits immunomodulatory and anti-inflammatory properties through regulation of interleukin-6 levels and increases in anti-inflammatory cytokines, making it therapeutically relevant for stress-related immune dysfunction and supporting overall neuroprotection.³,⁴

Selank is generally well-tolerated with a low side-effect profile, particularly compared to traditional anxiolytics, as it lacks risks of hypnosedation, myorelaxation, amnesia, withdrawal, or dependence.³,⁵,⁶ Common reported side effects, often mild and infrequent, include headache, nausea, dizziness, fatigue, nasal irritation (due to intranasal administration), and anxiety, though these have not been definitively confirmed as directly caused by Selank in clinical literature.⁵,⁶,⁷,⁸,⁹,¹⁰ Rare potential effects may encompass sinus pain, sore throat, drowsiness, mood swings, or allergic reactions, with administration-related issues like injection site reactions possible for subcutaneous use.³,⁵,⁶,¹⁰,¹¹ Key safety considerations involve monitoring for fever, flushing, blood pressure changes, irregular heart activity, or visual disturbances, avoiding use in pregnancy, breastfeeding, or active cancer, and noting FDA concerns over immunogenicity risks and limited human safety data for compounded formulations.³,⁵ It should only be used under medical supervision by qualified professionals, with dosing determined individually.³,⁷,¹⁰,¹² Long-term safety data remain developing.⁹

Selank acts as a synthetic analogue of the immunomodulatory peptide tuftsin, exerting its effects through allosteric modulation of GABA_A receptors, enhancing GABA binding affinity without direct ion channel activation or significant sedation.¹³,¹⁴,¹⁵ It influences monoamine neurotransmitter systems by modulating serotonin and dopamine metabolism, potentially inhibiting their reuptake, enhancing synthesis, and increasing receptor sensitivity, which contributes to anxiolytic and nootropic properties.⁹,¹³,¹⁵,¹⁶ Selank rapidly elevates brain-derived neurotrophic factor (BDNF) expression in the hippocampus, promoting neuronal growth and survival, while reducing pro-inflammatory cytokines like IL-6 and TNF-α to mitigate neuroinflammation.¹³,¹⁴,¹⁶ Additionally, it inhibits enzymes degrading enkephalins and other regulatory peptides, prolonging their activity in pain and emotional regulation pathways.¹³,¹⁴ These multifaceted actions on neurotransmitter, neurotrophic, and immune systems underlie its pharmacological profile.¹³,¹⁵,¹⁶